Targeting key factors in advanced prostate cancer treatment resistance
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers
['FUNDING_R37'] · STATE UNIVERSITY OF NEW YORK AT BUFFALO · NIH-10904810
This study is looking at how certain proteins in prostate cancer cells help the cancer resist treatments that target hormones, with the goal of finding new ways to improve treatment for patients who aren't responding to current therapies.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY OF NEW YORK AT BUFFALO (nih funded) |
| Locations | 1 site (AMHERST, UNITED STATES) |
| Trial ID | NIH-10904810 on ClinicalTrials.gov |
What this research studies
This research investigates how certain master regulatory transcription factors contribute to the resistance of advanced prostate cancer to androgen receptor-targeted therapies. By examining the mechanisms behind this resistance, the study aims to identify new therapeutic targets that could improve treatment outcomes for patients who have developed resistance to existing medications. The approach includes analyzing the expression of specific transcription factors and their impact on cancer cell survival and treatment response. Patients may benefit from insights that could lead to more effective treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced castrate-resistant prostate cancer who have experienced treatment resistance.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone androgen receptor-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that overcome resistance in advanced prostate cancer, improving survival and quality of life for patients.
How similar studies have performed: Other research has shown promising results in targeting similar mechanisms of resistance in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
AMHERST, UNITED STATES
- STATE UNIVERSITY OF NEW YORK AT BUFFALO — AMHERST, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ADELAIYE-OGALA, REMI — STATE UNIVERSITY OF NEW YORK AT BUFFALO
- Study coordinator: ADELAIYE-OGALA, REMI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Burden